Dignitana AB (publ) (DIGN.ST)
SEK 0.92
(-2.65%)
SEK 0.92
(-2.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 37.56 Million SEK | 9.52% |
| 2022 | 34.3 Million SEK | -14.61% |
| 2021 | 40.16 Million SEK | -33.33% |
| 2020 | 60.25 Million SEK | 128.35% |
| 2019 | 26.38 Million SEK | 3.85% |
| 2018 | 25.4 Million SEK | -18.43% |
| 2017 | 31.15 Million SEK | 291.15% |
| 2016 | 7.96 Million SEK | 16.19% |
| 2015 | 6.85 Million SEK | 4.74% |
| 2014 | 6.54 Million SEK | -5.31% |
| 2013 | 6.91 Million SEK | -5.43% |
| 2012 | 7.3 Million SEK | 23.26% |
| 2011 | 5.92 Million SEK | -26.42% |
| 2010 | 8.05 Million SEK | -15.8% |
| 2009 | 9.57 Million SEK | -12.26% |
| 2008 | 10.9 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 42.02 Million SEK | 11.87% |
| 2024 Q2 | 38.65 Million SEK | -8.02% |
| 2023 Q1 | 38.26 Million SEK | 11.56% |
| 2023 Q3 | 35.31 Million SEK | 3.49% |
| 2023 FY | 37.56 Million SEK | 9.52% |
| 2023 Q4 | 37.56 Million SEK | 6.37% |
| 2023 Q2 | 34.12 Million SEK | -10.82% |
| 2022 Q2 | 45.85 Million SEK | 11.31% |
| 2022 FY | 34.3 Million SEK | -14.61% |
| 2022 Q4 | 34.3 Million SEK | -33.24% |
| 2022 Q1 | 41.2 Million SEK | 2.57% |
| 2022 Q3 | 51.38 Million SEK | 12.05% |
| 2021 Q3 | 36.22 Million SEK | 5.31% |
| 2021 FY | 40.16 Million SEK | -33.33% |
| 2021 Q1 | 34.69 Million SEK | -42.42% |
| 2021 Q2 | 34.4 Million SEK | -0.84% |
| 2021 Q4 | 40.16 Million SEK | 10.88% |
| 2020 Q3 | 56.44 Million SEK | 44.08% |
| 2020 Q4 | 60.25 Million SEK | 6.75% |
| 2020 Q2 | 39.17 Million SEK | 18.01% |
| 2020 Q1 | 33.19 Million SEK | 25.82% |
| 2020 FY | 60.25 Million SEK | 128.35% |
| 2019 Q3 | 25.97 Million SEK | 30.34% |
| 2019 FY | 26.38 Million SEK | 3.85% |
| 2019 Q1 | 21.83 Million SEK | -14.05% |
| 2019 Q2 | 19.92 Million SEK | -8.76% |
| 2019 Q4 | 26.38 Million SEK | 1.6% |
| 2018 Q4 | 25.4 Million SEK | 25.79% |
| 2018 FY | 25.4 Million SEK | -18.43% |
| 2018 Q3 | 20.19 Million SEK | 29.14% |
| 2018 Q2 | 15.64 Million SEK | -2.94% |
| 2018 Q1 | 16.11 Million SEK | -48.27% |
| 2017 Q3 | 18.48 Million SEK | 51.09% |
| 2017 Q2 | 12.23 Million SEK | 55.72% |
| 2017 Q1 | 7.85 Million SEK | -1.36% |
| 2017 FY | 31.15 Million SEK | 291.15% |
| 2017 Q4 | 31.15 Million SEK | 68.54% |
| 2016 FY | 7.96 Million SEK | 16.19% |
| 2016 Q3 | 3.69 Million SEK | -55.88% |
| 2016 Q4 | 7.96 Million SEK | 115.6% |
| 2016 Q2 | 8.37 Million SEK | 115.12% |
| 2016 Q1 | 3.89 Million SEK | -43.22% |
| 2015 Q2 | 3.72 Million SEK | -4.88% |
| 2015 FY | 6.85 Million SEK | 4.74% |
| 2015 Q4 | 6.85 Million SEK | 5.05% |
| 2015 Q3 | 6.52 Million SEK | 74.93% |
| 2015 Q1 | 3.92 Million SEK | -40.08% |
| 2014 Q1 | 5.12 Million SEK | -25.8% |
| 2014 FY | 6.54 Million SEK | -5.31% |
| 2014 Q2 | 4.86 Million SEK | -5.2% |
| 2014 Q4 | 6.54 Million SEK | 28.21% |
| 2014 Q3 | 5.1 Million SEK | 5.0% |
| 2013 Q3 | 4.83 Million SEK | -21.01% |
| 2013 Q2 | 6.11 Million SEK | -0.22% |
| 2013 FY | 6.91 Million SEK | -5.43% |
| 2013 Q4 | 6.91 Million SEK | 43.07% |
| 2013 Q1 | 6.12 Million SEK | -16.14% |
| 2012 Q3 | 16.72 Million SEK | 71.36% |
| 2012 Q1 | 10.1 Million SEK | 70.41% |
| 2012 Q2 | 9.75 Million SEK | -3.41% |
| 2012 Q4 | 7.3 Million SEK | -56.3% |
| 2012 FY | 7.3 Million SEK | 23.26% |
| 2011 Q3 | 5.09 Million SEK | -49.29% |
| 2011 Q4 | 5.92 Million SEK | 16.36% |
| 2011 Q2 | 10.04 Million SEK | 65.41% |
| 2011 FY | 5.92 Million SEK | -26.42% |
| 2011 Q1 | 6.07 Million SEK | -24.61% |
| 2010 Q4 | 8.05 Million SEK | -17.17% |
| 2010 Q3 | 9.72 Million SEK | 3.97% |
| 2010 FY | 8.05 Million SEK | -15.8% |
| 2010 Q1 | 6.61 Million SEK | -30.86% |
| 2010 Q2 | 9.35 Million SEK | 41.4% |
| 2009 Q3 | 6.12 Million SEK | 13.64% |
| 2009 FY | 9.57 Million SEK | -12.26% |
| 2009 Q2 | 5.38 Million SEK | 0.0% |
| 2009 Q4 | 9.57 Million SEK | 56.29% |
| 2008 FY | 10.9 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -241.58% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.595% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.595% |
| Arcoma AB | 33.3 Million SEK | -12.797% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 88.606% |
| BICO Group AB (publ) | 3.26 Billion SEK | 98.849% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 86.578% |
| CellaVision AB (publ) | 212.32 Million SEK | 82.307% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -164.612% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -446.911% |
| C-Rad AB (publ) | 122.4 Million SEK | 69.308% |
| Duearity AB (publ) | 17.53 Million SEK | -114.301% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -89.732% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.848% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -82.361% |
| Iconovo AB (publ) | 14.55 Million SEK | -158.123% |
| Integrum AB (publ) | 22.07 Million SEK | -70.195% |
| Luxbright AB (publ) | 7 Million SEK | -436.662% |
| Mentice AB (publ) | 163.55 Million SEK | 77.031% |
| OssDsign AB (publ) | 105.25 Million SEK | 64.309% |
| Paxman AB (publ) | 44.5 Million SEK | 15.597% |
| Promimic AB (publ) | 16.15 Million SEK | -132.527% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 39.573% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -76.553% |
| ScandiDos AB (publ) | 37.18 Million SEK | -1.025% |
| Sectra AB (publ) | 1.64 Billion SEK | 97.711% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 14.741% |
| Senzime AB (publ) | 58.06 Million SEK | 35.302% |
| SpectraCure AB (publ) | 14.97 Million SEK | -150.865% |
| Stille AB | 172.64 Million SEK | 78.24% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 98.976% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 85.007% |